LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial

• DOI: 10.1016/j.annonc.2021.03.213
• Publication Date: 2021-05-08T17:01:42Z
• Authors: A. Bardia; D. Juric; T. Shimizu; A. Tolcher; R. Karim; A. Spira; T. Mukohara; A.E. Lisberg; T. Kogawa; I. Krop; K.P. Papadopoulos; E. Hamilton; S. Damodaran; J. Greenberg; W. Gu; F. Kobayashi; F. Guevara; T. Jikoh; Y. Kawasaki; F. Meric-Bernstam
• Keywords: Tolerability; Clinical endpoint